Frates James M's Form 4/A amendment
AmendedAmylyx Pharmaceuticals, Inc. (AMLX) · filed Mar 24, 2023
- Accession no.
- 0000899243-23-009602
- Filed
- Mar 24, 2023
- Trade date
- Mar 16, 2023
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 20, 2023
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.04M. It was filed 8 days after the trade.
This amendment replaces 0000899243-23-009168 (filed Mar 20, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Frates James MCIK 0001235598 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | Common Stock | MOption exerciseAcquired | +32,500 | $6.88 | +$223,600 | 66,509 | Direct | |
| Mar 16, 2023 | Common Stock | SSaleDisposed | −30,796 | $31.86F3 | −$981,160.56 | 35,713 | Direct | |
| Mar 16, 2023 | Common Stock | SSaleDisposed | −1,704 | $32.46F4 | −$55,311.84 | 34,009 | Direct | |
| Mar 16, 2023 | Common Stock | AGrant or awardAcquired | +21,667 | $0.00 | $0 | 55,676 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | Common Stock | AGrant or awardAcquired | +97,500 | $0.00 | $0 | 97,500 | Direct | |
| Mar 16, 2023 | Common Stock | MOption exerciseDisposed | −32,500 | $0.00 | $0 | 414,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
- F2
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
- F6
1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
- F7
113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.
Remarks
Exhibit List: Exhibit 24. This signed and dated Power of Attorney is being filed to replace the Power of Attorney exhibit submitted with the Form 3 filed on January 6, 2022.